Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -43.42% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-43.42%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-3.36%
vs the sector median at left
Atrium Therapeutics, Inc.
Market Cap
$136.67M
Return on Equity (ROE)
-43.42%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$136.57M
Return on Equity (ROE)
15.55%
TTM Avg
-9.97%
3Y Avg
-34.81%
5Y Avg
-26.89%
Market Cap
$137.80M
Return on Equity (ROE)
-10.08%
TTM Avg
-25.77%
3Y Avg
-36.68%
5Y Avg
-27.09%
Market Cap
$139.04M
Return on Equity (ROE)
-30.03%
TTM Avg
-86.56%
3Y Avg
-69.53%
5Y Avg
-37.30%
Market Cap
$139.47M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
Market Cap
$139.84M
Return on Equity (ROE)
N/A
TTM Avg
-182.86%
3Y Avg
-123.00%
5Y Avg
-90.58%
Market Cap
$132.03M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$131.21M
Return on Equity (ROE)
-11.20%
TTM Avg
-11.86%
3Y Avg
-12.45%
5Y Avg
-5.17%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | $136.67M | -43.42% | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $136.57M | 15.55% | -9.97% | -34.81% | -26.89% |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.80M | -10.08% | -25.77% | -36.68% | -27.09% |
| Immuneering Corporation (IMRX)vs › | $139.04M | -30.03% | -86.56% | -69.53% | -37.30% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -44.26% | -34.18% | 285.39% | -5868.11% |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | N/A | -182.86% | -123.00% | -90.58% |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $132.03M | -266.86% | 156.76% | 98.17% | -694.29% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | -11.20% | -11.86% | -12.45% | -5.17% |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | -262.64% | -45.72% | -38.99% | -37.83% |
ROE
-43.4%
ROA
-33.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -43.42% |
